Exelixis, Inc.Exelixis, Inc.Exelixis, Inc.

Exelixis, Inc.

No trades
See on Supercharts

EXEL fundamentals

Key facts

Market capitalization

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.


Fundamental metrics to determine fair value of the stock

No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins


Dividend yield, history and sustainability

EXEL does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company